secwatch.observer — SEC 8-K summary
======================================

Issuer:     NUGENEREX IMMUNO-ONCOLOGY, INC. (—)
CIK:        0001804585
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001804585-23-000007
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.01, 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Beijing Youfeng acquires 64% of NuGenerex for $3.35M in bankruptcy; new board and CEO appointed
--------------------------------------------------------------------------------

- Beijing Youfeng Biological Technology acquired 64,153,151 common shares (63.96%) and 100% of Series A Super Voting Preferred on March 3, 2023 for $3.35 million.
- Control assumed from Chapter 7 Trustee Marc P. Barmat of Generex Biotechnology's bankruptcy estate.
- On March 15, 2023, majority shareholder elected new directors: XiaoYan Wang, Feng Wang, and Kevin McGovern via written consent.
- New board on March 21, 2023 removed all officers except Dr. Eric von Hofe; appointed Feng Wang as CEO, Secretary, Treasurer; von Hofe as President and CSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/plain8k.txt
  HTML page:      https://secwatch.observer/filing/0001804585-23-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer